Figure 7.

Monocyte-derived DCs are sufficient for the recruitment of CD8⁺ T cells to tumors and the activation of antitumor immunity. (A) Schematic representation of experimental design. C57BL/6 WT (C57WT) or CD11c-DTR BM chimeras were injected with B16 melanoma tumors, treated every second day for four times with MSU + Msmeg or PBS, and at the same time depleted of CD11c⁺ cells by DT treatment as indicated. Some of these mice were also injected with WT BM monocytes to obtain mice where moDC populations could only originate from the injected monocytes. (B) Mice were treated as in (A), except that tumors were B16.OVA, and all mice also received naive OTI cells given at the time of the second dose of immunotherapy. Graphs show the percentage of CD8⁺ T cells (CD45⁺CD4⁻CD8⁺) and OTI cells (CD45⁺CD4⁻CD8⁺CD45.1⁺) among total live cells in tumors 2 days after the fourth MSU + Msmeg treatment. Data are pooled from two independent experiments each with 5 mice/group. Graphs show mean + SEM. Statistical analysis used a Kruskal–Wallis test with Dunn’s post-test. (C) Mean tumor sizes + SEM on day 21 after tumor challenge. Data are pooled from three independent experiments each with 5 mice/group. Statistical analysis was by ANOVA with Tukey’s post-test. (D) Survival data, pooled from two independent experiments each with 5 mice/group. Statistical significance was evaluated using a log-rank test and Bonferroni’s correction.